{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:34:48Z","timestamp":1793896488805,"version":"4.8.0"},"reference-count":150,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Older adults with acute myeloid leukemia (AML) represent a cancer population in which disease-based risk factors, comorbidities, patient goals, and treatment risks and benefits influence treatment recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>These evidence-based guidelines from the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health professionals in their decisions about management of AML in older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ASH formed a multidisciplinary guideline panel, including patient representatives, that minimized bias from conflicts of interest. Clarity Research Group at McMaster University supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized questions and outcomes according to their importance for clinicians and patients. The panel used the grading of recommendations assessment, development and evaluation approach, including evidence-to-decision frameworks, to assess evidence and make recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The panel agreed on 9 critical clinical recommendations for managing AML in older adults, mirroring real-time practitioner-patient conversations: the decision to pursue antileukemic treatment vs best supportive management; traditional induction and postremission therapy vs hypomethylating agent or low-dose cytarabine, or combinations with venetoclax; the role and duration of postremission therapy; combinations with venetoclax vs monotherapy; the use of targeted therapy, including isocitrate dehydrogenase and FMS-like tyrosine kinase 3 (FLT3) inhibitors, in appropriate patients; the role of hematopoietic stem cell transplantation in nonfavorable prognosis AML; and the role of transfusion support for patients no longer receiving antileukemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Key recommendations of these guidelines include treatment over best supportive care; venetoclax-based regimens over monotherapies; and incorporation of FLT3 inhibitors into traditional induction and postremission therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017934","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T09:51:16Z","timestamp":1764582676000},"page":"1897-1928","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-6524","authenticated-orcid":false,"given":"Mikkael A.","family":"Sekeres","sequence":"first","affiliation":[{"name":"1Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8574-8365","authenticated-orcid":false,"given":"Ryan","family":"Mattison","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin-Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-9607","authenticated-orcid":false,"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[{"name":"3Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-1348","authenticated-orcid":false,"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-3288","authenticated-orcid":false,"given":"Chong Chyn","family":"Chua","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Monash Hospital, Monash University and Northern Hospital Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0258-7397","authenticated-orcid":false,"given":"Roberta","family":"Demichelis-G\u00f3mez","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Oncology, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-2916","authenticated-orcid":false,"given":"Pamela C.","family":"Egan","sequence":"additional","affiliation":[{"name":"7Department of Medicine, MaineHealth Cancer Center, South Portland, ME"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2384-536X","authenticated-orcid":false,"given":"Luke","family":"Fletcher","sequence":"additional","affiliation":[{"name":"8Division of Medical Oncology, Willamette Valley Cancer Institute, Eugene, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8678-9656","authenticated-orcid":false,"given":"Charles","family":"Foucar","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine, Division of Hematology and Oncology, The University of New Mexico, Albuquerque, NM"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2118-6302","authenticated-orcid":false,"given":"Jacqueline S.","family":"Garcia","sequence":"additional","affiliation":[{"name":"10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gilberto","sequence":"additional","affiliation":[{"name":"11Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6904-9345","authenticated-orcid":false,"given":"Andres","family":"G\u00f3mez de Le\u00f3n","sequence":"additional","affiliation":[{"name":"12Division of Hematology, Department of Internal Medicine, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7751-7310","authenticated-orcid":false,"given":"Jeffrey","family":"Lancet","sequence":"additional","affiliation":[{"name":"13Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6978-0418","authenticated-orcid":false,"given":"Kah Poh","family":"Loh","sequence":"additional","affiliation":[{"name":"14Division of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1460-1611","authenticated-orcid":false,"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[{"name":"15Department of Molecular Medicine, University of Pavia and San Matteo University Hospital Foundation, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0436-8948","authenticated-orcid":false,"given":"Bernard","family":"Marini","sequence":"additional","affiliation":[{"name":"16Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"17Department of Internal Medicine, University Hospital Carl Gustav Carus, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5260-1981","authenticated-orcid":false,"given":"Mohamed L.","family":"Sorror","sequence":"additional","affiliation":[{"name":"18Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3012-7398","authenticated-orcid":false,"given":"Sara","family":"Tinsley-Vance","sequence":"additional","affiliation":[{"name":"13Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Treitz","sequence":"additional","affiliation":[{"name":"19Louisville, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9327-6844","authenticated-orcid":false,"given":"Maria Jose","family":"Oliveros","sequence":"additional","affiliation":[{"name":"20Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"},{"name":"21Departamento de Ciencias de la Rehabilitaci\u00f3n, Facultad de Medicina, Universidad de La Frontera, Temuco, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7713-6171","authenticated-orcid":false,"given":"Sara","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"20Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4564-5973","authenticated-orcid":false,"given":"Yetiani","family":"Roldan","sequence":"additional","affiliation":[{"name":"20Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-5718","authenticated-orcid":false,"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[{"name":"20Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6010-9900","authenticated-orcid":false,"given":"Romina","family":"Brignardello-Petersen","sequence":"additional","affiliation":[{"name":"20Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2026032014062727500_bib1","author":"Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines","year":"2011"},{"issue":"7","key":"2026032014062727500_bib2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"issue":"7","key":"2026032014062727500_bib3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Sch\u00fcnemann","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026032014062727500_bib4","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"2026032014062727500_bib5","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"2026032014062727500_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"2026032014062727500_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"2026032014062727500_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"2026032014062727500_bib9","first-page":"677","article-title":"Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations","volume":"169","author":"Sch\u00fcnemann","year":"2003","journal-title":"CMAJ"},{"key":"2026032014062727500_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","article-title":"GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health","volume":"76","author":"Sch\u00fcnemann","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2026032014062727500_bib11","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Program\n          . Cancer Stat Facts: Leukemia-Acute Myeloid Leukemia (AML). SEER. Accessed 2 October 2019. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"issue":"9","key":"2026032014062727500_bib12","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2026032014062727500_bib13","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"issue":"11","key":"2026032014062727500_bib14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3324\/haematol.2018.191536","article-title":"Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older","volume":"103","author":"Prassek","year":"2018","journal-title":"Haematologica"},{"issue":"33","key":"2026032014062727500_bib15","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1200\/JCO.2009.22.2547","article-title":"Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia","volume":"27","author":"Rao","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026032014062727500_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-024-01033-7","article-title":"Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century","volume":"14","author":"Hemminki","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026032014062727500_bib17","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Sch\u00fcnemann","year":"2014","journal-title":"CMAJ"},{"key":"2026032014062727500_bib18","author":"Institute of Medicine (US) Committee on Conflict of Interest in Medical Research, Education, and Practice","year":"2009"},{"issue":"11","key":"2026032014062727500_bib19","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jclinepi.2014.05.006","article-title":"Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study","volume":"67","author":"Akl","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2026032014062727500_bib20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-152-11-201006010-00254","article-title":"The vexing problem of guidelines and conflict of interest: a potential solution","volume":"152","author":"Guyatt","year":"2010","journal-title":"Ann Intern Med"},{"issue":"6","key":"2026032014062727500_bib21","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1164\/rccm.200901-0126ST","article-title":"An official American Thoracic Society Policy statement: managing conflict of interest in professional societies","volume":"180","author":"Sch\u00fcnemann","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2026032014062727500_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2026032014062727500_bib23","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5","year":"2024"},{"key":"2026032014062727500_bib149","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026032014062727500_bib150","volume-title":"Cochrane Methods","year":"2016"},{"issue":"1","key":"2026032014062727500_bib78","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","article-title":"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study","volume":"35","author":"Montesinos","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"2026032014062727500_bib24","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1002\/ajh.26546","article-title":"Outcomes of TP53-mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival","volume":"97","author":"Badar","year":"2022","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2026032014062727500_bib25","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1016\/S2152-2650(23)01013-3","article-title":"Characteristics and outcomes of patients with acute myeloid leukemia and DDX41 mutation","volume":"23","author":"Bataller","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"2026032014062727500_bib26","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/bloodadvances.2022009391","article-title":"Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity","volume":"7","author":"Bazinet","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2026032014062727500_bib27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-021-00435-1","article-title":"Mayo Clinic experience with 1123 adults with acute myeloid leukemia","volume":"11","author":"Begna","year":"2021","journal-title":"Blood Cancer J"},{"issue":"24","key":"2026032014062727500_bib28","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"key":"2026032014062727500_bib29","doi-asserted-by":"crossref","first-page":"106904","DOI":"10.1016\/j.leukres.2022.106904","article-title":"Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA\/venetoclax","volume":"119","author":"Chojecki","year":"2022","journal-title":"Leuk Res"},{"issue":"8","key":"2026032014062727500_bib30","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.26941","article-title":"Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion","volume":"98","author":"Daver","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"2026032014062727500_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2026032014062727500_bib32","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41409-023-01977-7","article-title":"Impact of induction intensity and transplantation on outcomes of patients with complex karyotype and TP53-mutated acute myeloid leukemia","volume":"58","author":"Jamy","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"2026032014062727500_bib33","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2026032014062727500_bib34","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/ajh.26694","article-title":"Contemporary outcomes in IDH-mutated acute myeloid leukemia: the impact of co-occurring NPM1 mutations and venetoclax-based treatment","volume":"97","author":"Lachowiez","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"2026032014062727500_bib35","doi-asserted-by":"crossref","first-page":"2230738","DOI":"10.1080\/16078454.2023.2230738","article-title":"Analysis and clinical characteristics of acute myeloid leukemia developing with prior or concurrent tumors in non cyto- or radiotherapy exposure patients in a single center","volume":"28","author":"Lian","year":"2023","journal-title":"Hematology"},{"issue":"11","key":"2026032014062727500_bib36","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(23)00273-9","article-title":"10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial","volume":"10","author":"L\u00fcbbert","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"2026032014062727500_bib37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"2026032014062727500_bib38","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.26991","article-title":"Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia","volume":"98","author":"Matthews","year":"2023","journal-title":"Am J Hematol"},{"issue":"13","key":"2026032014062727500_bib39","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026032014062727500_bib40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-022-01229-z","article-title":"Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure","volume":"15","author":"Short","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2026032014062727500_bib41","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.26724","article-title":"Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia","volume":"97","author":"Venugopal","year":"2022","journal-title":"Am J Hematol"},{"issue":"19","key":"2026032014062727500_bib42","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1002\/cncr.33675","article-title":"Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy","volume":"127","author":"Venugopal","year":"2021","journal-title":"Cancer"},{"issue":"4","key":"2026032014062727500_bib43","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00277-023-05109-5","article-title":"Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States","volume":"102","author":"Zeidan","year":"2023","journal-title":"Ann Hematol"},{"issue":"5","key":"2026032014062727500_bib44","first-page":"1484","article-title":"Clinical comparation of two kinds of chemotherapy regimen in the treatment of elderly MDS patients with AML transformed by abnormal proliferation of bone marrow","volume":"24","author":"Zhou","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"2","key":"2026032014062727500_bib45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/10428194.2020.1832662","article-title":"Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists","volume":"62","author":"Loh","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"2026032014062727500_bib46","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/bloodadvances.2024013685","article-title":"Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy","volume":"8","author":"Hoff","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2026032014062727500_bib47","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study","volume":"37","author":"Mr\u00f3zek","year":"2023","journal-title":"Leukemia"},{"issue":"34","key":"2026032014062727500_bib48","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1200\/JCO.23.02631","article-title":"Risk stratification in older intensively treated patients with AML","volume":"42","author":"Versluis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"13","key":"2026032014062727500_bib49","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients","volume":"133","author":"Huls","year":"2019","journal-title":"Blood"},{"issue":"13","key":"2026032014062727500_bib50","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study","volume":"115","author":"L\u00f6wenberg","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2026032014062727500_bib51","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3390\/cancers15092441","article-title":"Azacitidine post-remission therapy for elderly patients with AML: a randomized phase-3 trial (QoLESS AZA-AMLE)","volume":"15","author":"Oliva","year":"2023","journal-title":"Cancers"},{"issue":"26","key":"2026032014062727500_bib52","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"2026032014062727500_bib53","doi-asserted-by":"crossref","first-page":"101529","DOI":"10.1016\/j.jgo.2023.101529","article-title":"Patient preferences, regret, and health-related quality of life among older adults with acute myeloid leukemia: a pilot longitudinal study","volume":"14","author":"LoCastro","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"2026032014062727500_bib54","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/1055-9965.EPI-19-1277","article-title":"Age at diagnosis and patient preferences for treatment outcomes in AML: a discrete choice experiment to explore meaningful benefits","volume":"29","author":"Richardson","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"2026032014062727500_bib55","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1080\/03007995.2018.1456414","article-title":"Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development","volume":"34","author":"Seo","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2026032014062727500_bib56","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/blood.2022016916","article-title":"An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML","volume":"141","author":"Sorror","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026032014062727500_bib57","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.leukres.2010.07.020","article-title":"Race and intensity of post-remission therapy in acute myeloid leukemia","volume":"35","author":"Brady","year":"2011","journal-title":"Leuk Res"},{"issue":"7","key":"2026032014062727500_bib58","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"2026032014062727500_bib59","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2026032014062727500_bib60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/10428194.2022.2148212","article-title":"A randomized phase II\/III study of \u2018novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612","volume":"64","author":"Assouline","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2026032014062727500_bib61","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2011.59","article-title":"The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome","volume":"25","author":"Burnett","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"2026032014062727500_bib62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2012.229","article-title":"The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison","volume":"27","author":"Burnett","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"2026032014062727500_bib63","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/bjh.19220","article-title":"A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: results from the LI-1 trial","volume":"204","author":"Copland","year":"2024","journal-title":"Br J Haematol"},{"issue":"2","key":"2026032014062727500_bib64","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"2026032014062727500_bib65","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bjh.17501","article-title":"A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial","volume":"194","author":"Dennis","year":"2021","journal-title":"Br J Haematol"},{"issue":"24","key":"2026032014062727500_bib66","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1182\/bloodadvances.2021005038","article-title":"Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients","volume":"5","author":"Dennis","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2026032014062727500_bib67","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"2026032014062727500_bib68","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"2026032014062727500_bib69","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","article-title":"Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy","volume":"124","author":"D\u00f6hner","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2026032014062727500_bib70","doi-asserted-by":"crossref","first-page":"E617","DOI":"10.1097\/HS9.0000000000000617","article-title":"Adjunctive volasertib in patients with acute myeloid leukemia not eligible for standard induction therapy: a randomized, phase 3 trial","volume":"5","author":"D\u00f6hner","year":"2021","journal-title":"Hemasphere"},{"issue":"4","key":"2026032014062727500_bib71","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026032014062727500_bib72","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/bloodadvances.2020002846","article-title":"Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS","volume":"4","author":"Huls","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2026032014062727500_bib73","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3324\/haematol.2018.201152","article-title":"Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia","volume":"104","author":"Kenealy","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"2026032014062727500_bib74","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.19.01053","article-title":"Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 x 2, phase II trial","volume":"38","author":"L\u00fcbbert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026032014062727500_bib75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.2017.172353","article-title":"Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia","volume":"103","author":"Medeiros","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"2026032014062727500_bib76","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/leu.2016.303","article-title":"A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials","volume":"31","author":"Montalban-Bravo","year":"2017","journal-title":"Leukemia"},{"issue":"16","key":"2026032014062727500_bib77","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"2026032014062727500_bib79","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.18560","article-title":"A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: results from the LI-1 trial","volume":"200","author":"Mussai","year":"2023","journal-title":"Br J Haematol"},{"key":"2026032014062727500_bib80","doi-asserted-by":"crossref","first-page":"858202","DOI":"10.3389\/fonc.2022.858202","article-title":"Outcomes of newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: a propensity score-adjusted cohort study","volume":"12","author":"Mustafa Ali","year":"2022","journal-title":"Front Oncol"},{"issue":"12","key":"2026032014062727500_bib81","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026032014062727500_bib82","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1182\/bloodadvances.2018023689","article-title":"Randomized trial of 10 days of decitabine \u00b1 bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)","volume":"2","author":"Roboz","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2026032014062727500_bib83","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3324\/haematol.2012.066613","article-title":"Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia","volume":"98","author":"Sekeres","year":"2013","journal-title":"Haematologica"},{"issue":"10","key":"2026032014062727500_bib84","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-023-02001-z","article-title":"Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial","volume":"37","author":"Sekeres","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2026032014062727500_bib85","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","article-title":"Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial","volume":"6","author":"Short","year":"2019","journal-title":"Lancet Haematol"},{"issue":"12","key":"2026032014062727500_bib86","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/cncr.33403","article-title":"A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia","volume":"127","author":"Vives","year":"2021","journal-title":"Cancer"},{"issue":"17","key":"2026032014062727500_bib87","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2026032014062727500_bib88","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2026032014062727500_bib89","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2026032014062727500_bib90","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jha2.663","article-title":"Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia","volume":"4","author":"Bouligny","year":"2023","journal-title":"eJHaem"},{"issue":"4","key":"2026032014062727500_bib91","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/ajh.26846","article-title":"Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with venetoclax","volume":"98","author":"Candoni","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"2026032014062727500_bib92","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/1120009X.2022.2097433","article-title":"Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience","volume":"35","author":"Chen","year":"2023","journal-title":"J Chemother"},{"key":"2026032014062727500_bib93","doi-asserted-by":"crossref","first-page":"106803","DOI":"10.1016\/j.leukres.2022.106803","article-title":"Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience","volume":"114","author":"De Bellis","year":"2022","journal-title":"Leuk Res"},{"issue":"1","key":"2026032014062727500_bib94","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2026032014062727500_bib95","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2026032014062727500_bib96","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/j.clml.2023.02.002","article-title":"Early real-world first-line treatment with venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominately US community setting","volume":"23","author":"Gershon","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"2026032014062727500_bib97","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naive acute myeloid leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2026032014062727500_bib98","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2022-171105","article-title":"Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score matched analysis","volume":"140","author":"Kwag","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026032014062727500_bib99","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","article-title":"Hypomethylating agent and venetoclax with FLT3 inhibitor \u201ctriplet\u201d therapy in older\/unfit patients with FLT3 mutated AML","volume":"12","author":"Yilmaz","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026032014062727500_bib100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-024-01000-2","article-title":"Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"14","author":"Badar","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026032014062727500_bib101","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-naive TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"24","key":"2026032014062727500_bib102","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2026032014062727500_bib103","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","article-title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial","volume":"100","author":"Heuser","year":"2021","journal-title":"Ann Hematol"},{"issue":"4","key":"2026032014062727500_bib104","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2026032014062727500_bib105","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2026032014062727500_bib106","first-page":"331","article-title":"Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: real experience data","volume":"9","author":"Karakus","year":"2022","journal-title":"North Clin Istanb"},{"key":"2026032014062727500_bib107","unstructured":"Chan\n              O\n            \n          . Discontinuation of hypomethylating agent and venetoclax in patients with newly diagnosed acute myeloid leukemia (AML) who have achieved negative measurable residual disease (MRD). Updated 15 December 2025. ClinicalTrials.gov identifier: NCT06511882. Accessed 10 June 2025. https:\/\/clinicaltrials.gov\/study\/NCT06511882."},{"key":"2026032014062727500_bib108","unstructured":"Institut Paoli-Calmettes\n          . De-escalation study evaluating venetoclax and azacitidine discontinuation in AML responding patients. Updated 18 June 2025. ClinicalTrials.gov identifier: NCT06557421. Accessed 10 June 2025. https:\/\/clinicaltrials.gov\/study\/NCT06557421."},{"issue":"10388","key":"2026032014062727500_bib109","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"2026032014062727500_bib110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41408-020-0318-1","article-title":"Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia","volume":"10","author":"Abou Dalle","year":"2020","journal-title":"Blood Cancer J"},{"issue":"18","key":"2026032014062727500_bib111","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","article-title":"Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications","volume":"6","author":"D\u00f6hner","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2026032014062727500_bib112","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2026032014062727500_bib113","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1182\/bloodadvances.2021004435","article-title":"In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study","volume":"6","author":"Devillier","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2026032014062727500_bib114","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00432-021-03733-0","article-title":"Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia","volume":"148","author":"Fleischmann","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"2026032014062727500_bib115","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/S2352-3026(15)00148-9","article-title":"Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis","volume":"2","author":"Versluis","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026032014062727500_bib116","first-page":"68","article-title":"Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study","volume":"110","author":"Niederwieser","year":"2025","journal-title":"Haematologica"},{"issue":"4","key":"2026032014062727500_bib117","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00277-020-03922-w","article-title":"Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome","volume":"99","author":"Bouchacourt","year":"2020","journal-title":"Ann Hematol"},{"issue":"12","key":"2026032014062727500_bib118","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.bbmt.2011.06.005","article-title":"Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission","volume":"17","author":"Farag","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"33","key":"2026032014062727500_bib119","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia","volume":"40","author":"Kadia","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026032014062727500_bib120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbmt.2010.07.013","article-title":"Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission","volume":"17","author":"Kurosawa","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2026032014062727500_bib121","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026032014062727500_bib122","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000437131","article-title":"High-intensity induction chemotherapy is feasible for elderly patients with acute myeloid leukemia","volume":"135","author":"Shacham-Abulafia","year":"2016","journal-title":"Acta Haematol"},{"issue":"5","key":"2026032014062727500_bib123","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41409-023-01925-5","article-title":"Comparison of haploidentical hematopoietic stem cell transplantation with chemotherapy in older adults with acute myeloid leukemia","volume":"58","author":"Sun","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"2026032014062727500_bib124","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","article-title":"Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study","volume":"33","author":"Ustun","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"2026032014062727500_bib125","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.23576","article-title":"Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status","volume":"88","author":"Yoon","year":"2013","journal-title":"Am J Hematol"},{"issue":"12","key":"2026032014062727500_bib126","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.bbmt.2011.06.005","article-title":"Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission","volume":"17","author":"Farag","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2026032014062727500_bib127","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbmt.2010.07.013","article-title":"Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission","volume":"17","author":"Kurosawa","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2026032014062727500_bib128","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2026032014062727500_bib129","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","article-title":"Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study","volume":"33","author":"Ustun","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"2026032014062727500_bib130","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2026032014062727500_bib131","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"issue":"3","key":"2026032014062727500_bib132","doi-asserted-by":"crossref","first-page":"280","DOI":"10.6004\/jnccn.2011.0027","article-title":"Acute myeloid leukemia","volume":"9","author":"O'Donnell","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"2026032014062727500_bib133","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"issue":"suppl 1","key":"2026032014062727500_bib134","first-page":"6-6","article-title":"Impact of socioeconomic factors on access to and outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML): a multi-center observational study","volume":"144","author":"Wuliji","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026032014062727500_bib135","first-page":"578.e1","article-title":"Impact of donor age on allogeneic hematopoietic cell transplantation outcomes in older adults with acute myeloid leukemia","volume":"29","author":"Abid","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"2026032014062727500_bib136","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41409-022-01650-5","article-title":"Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis","volume":"57","author":"Maakaron","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"2026032014062727500_bib137","first-page":"3533","article-title":"Prognostic impact of \u2018multi-hit' versus \u2018single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases","volume":"109","author":"Badar","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"2026032014062727500_bib138","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2026032014062727500_bib139","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"2026032014062727500_bib140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41409-024-02447-4","article-title":"Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2026032014062727500_bib141","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41409-024-02449-2","article-title":"Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2026032014062727500_bib142","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41409-024-02444-7","article-title":"Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Hegde","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"2026032014062727500_bib143","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/s41375-024-02275-x","article-title":"Recommendations from the AML molecular MRD expert advisory board","volume":"38","author":"Scott","year":"2024","journal-title":"Leukemia"},{"issue":"16 suppl","key":"2026032014062727500_bib144","first-page":"7006-7006","article-title":"Pre-MEASURE: multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission","volume":"40","author":"Hourigan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026032014062727500_bib145","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.clml.2021.07.010","article-title":"Predictive factors for outcome of first allogeneic transplant for elderly patients with acute lymphoblastic leukemia","volume":"21","author":"Bazarbachi","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2026032014062727500_bib146","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/ajh.26834","article-title":"Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia","volume":"98","author":"Guru Murthy","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"2026032014062727500_bib147","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41375-024-02497-z","article-title":"Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia","volume":"39","author":"Orvain","year":"2025","journal-title":"Leukemia"},{"key":"2026032014062727500_bib148","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT","volume":"81","author":"Sch\u00fcnemann","year":"2017","journal-title":"J Clin Epidemiol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/1897\/2508117\/blooda_adv-2025-017934-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/1897\/2508117\/blooda_adv-2025-017934-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:06:45Z","timestamp":1774030005000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/6\/1897\/548455\/American-Society-of-Hematology-2025-guidelines-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":150,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017934","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,24]]},"published":{"date-parts":[[2026,3,11]]}}}